Venn Life Sciences Acquires Kinesis Pharma

Linus Health Acquires Kinesis Health Technologies

March 30, 2022

Medical Devices

Boston-based digital health company Linus Health has acquired Dublin-based Kinesis Health Technologies, a developer of validated digital assessments for gait, balance, mobility, and falls risk in older adults. The acquisition expands Linus Health's brain health platform by adding physical-function measurement capabilities to improve early detection and clinical guidance.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.

Bayer Acquires UK Biotech KaNDy Therapeutics Ltd.

August 11, 2020

Biotechnology

Bayer has agreed to acquire UK-based clinical-stage biotech KaNDy Therapeutics Ltd. for an upfront $425 million with up to $450 million in additional milestone payments, expanding Bayer's women's healthcare drug development pipeline—specifically the investigational non-hormonal compound NT-814 for menopausal vasomotor symptoms. The acquisition, subject to customary conditions, was announced in August 2020 and is expected to close in September 2020.

VelocityEHS Acquires Kinetica Labs

July 21, 2021

AI & Machine Learning

VelocityEHS, the Chicago-based provider of cloud EHS and sustainability software, has acquired Ann Arbor-based Kinetica Labs, a developer of sensorless motion-capture and computer vision technology for workplace ergonomics. The acquisition brings Kinetica's AI and machine-learning capabilities into VelocityEHS's Industrial Ergonomics solution to accelerate product innovation and automated MSD risk assessments.

Charles River Laboratories Acquires Vigene Biosciences

May 17, 2021

Biotechnology

Charles River Laboratories agreed to acquire Vigene Biosciences, a Rockville, Maryland-based gene therapy CDMO, for $292.5 million in cash plus up to $57.5 million in contingent payments. The acquisition expands Charles River's cell and gene therapy contract development and manufacturing capabilities—adding CGMP viral vector and plasmid DNA production—and is expected to close in early Q3 2021.

Vālenz Acquires Kozani Health

April 5, 2021

Healthcare Services

Vālenz, a Great Point Partners-backed healthcare platform, has acquired Kozani Health and integrated its bill review and claim management services as Valenz ProteKHt. The add-on expands Vālenz's payment integrity and claim management capabilities for self-funded and self-insured employers.